Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Second quarter financial results. As an exploration company, Aurania does not generate revenue and has expenses to advance its projects. During the second quarter of 2025, the company generated a net loss of C$1,610,843 or C$0.01 per share. We had projected a loss of C$1,432,419 or C$0.01 per share. The variance to our estimate was mostly due to higher exploration expenditures, along with higher stock-based compensation. We project a full-year 2025 net loss of C$11.1 million, or C$(0.10) per share, compared to our prior loss estimate of C$10.5 million, or C$(0.09) per share.
Mining service fee. Ecuador recently implemented a new mining service fee on the resource sector (refer to our note dated July 29, 2025). The Ecuadorian Control and Regulation Agency (ARCOM) requested payment from Aurania of US$2,012,618 by July 31, 2025, representing one month of the total annual fee of US$24,151,420. While the penalty for non-payment is unclear, we think Aurania is withholding payment until it becomes clear whether TASA will stand in its current form due to multiple constitutional challenges.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
U.S. consumer spending rose more than expected in August, reinforcing the strength of the economy even as inflation continued to edge higher. The Commerce Department reported that household expenditures advanced 0.6% last month, surpassing forecasts of a 0.5% gain and extending July’s 0.5% increase. The results suggest that the economy maintained much of its momentum from the second quarter, when growth hit its fastest pace in nearly two years.
Households increased spending across both services and goods. Travel and leisure categories saw notable gains, with more Americans booking airline tickets, staying in hotels, and dining out. Spending at restaurants and bars remained elevated, while recreational services also benefited from strong demand.
Goods purchases rose 0.8% in August, driven by sales of recreational equipment, clothing, and gasoline. Services spending, which accounts for the bulk of household consumption, advanced 0.5%, in line with the previous month.
This broad-based spending has been supported by wealth gains among higher-income households. Rising stock prices and elevated home values have bolstered balance sheets, allowing affluent consumers to maintain strong levels of discretionary spending. By contrast, lower-income families continue to face challenges from higher food and energy costs, as well as upcoming reductions in federal nutrition assistance programs.
The Personal Consumption Expenditures (PCE) Price Index, the Federal Reserve’s preferred inflation gauge, climbed 0.3% in August following a 0.2% gain in July. On a year-over-year basis, prices rose 2.7%, the largest annual increase since February. Core PCE, which excludes volatile food and energy categories, remained elevated at 2.9%.
The acceleration in prices reflects the lingering impact of tariffs and supply constraints. Many businesses have so far absorbed part of the higher costs rather than pass them directly to consumers, but economists caution that this trend is unlikely to continue indefinitely. As inventories accumulated before tariffs are depleted, broader price pressures could emerge.
Personal income rose 0.4% in August, with a significant portion of the gain stemming from government transfer payments. Wage growth was comparatively modest at 0.3%, highlighting persistent weakness in the labor market. Job creation has slowed considerably in recent months due to policy uncertainty and tighter immigration rules, which have limited labor supply.
This divergence between resilient spending and softer hiring raises questions about the durability of consumption in the months ahead. While households are still fueling growth today, slower income gains could eventually restrain demand, especially if inflation remains elevated.
The Atlanta Fed currently projects third-quarter GDP growth of 3.3%, down slightly from the 3.8% expansion recorded in the second quarter. Analysts expect consumer spending to cool toward the end of the year as higher prices weigh on purchasing power and government support programs wind down.
For now, household consumption remains the key driver of U.S. economic expansion. Whether this momentum can continue in the face of rising inflation and labor market challenges will be a central focus for policymakers and investors heading into the final quarter of 2025.
President Donald Trump unveiled a sweeping new round of tariffs on Thursday, targeting industries from pharmaceuticals to heavy trucks and furniture in what marks one of the most aggressive expansions of his trade agenda to date. The tariffs will range from 30% to 100%, with the heaviest duties falling on patented prescription drugs unless their producers establish manufacturing facilities within the United States.
The pharmaceutical sector sits at the center of the new policy. Under the plan, companies that are not actively building domestic plants face tariffs as high as 100% on patented drugs imported into the U.S. The administration has framed the move as a way to push drugmakers to “reshore” production after years of relying on overseas supply chains.
The measures add new layers to Trump’s already extensive tariff program, which has been rolled out in waves since 2018. While the pharmaceutical duties were previewed earlier this year, the inclusion of industries such as furniture and heavy trucks represents a new front in the administration’s trade efforts.
The White House is also signaling plans to reshape semiconductor supply chains. According to administration officials, chipmakers will be asked to manufacture in the U.S. at least as many chips as they sell domestically, with tariffs applied to firms that fail to meet a 1:1 production-to-import ratio. The move comes amid concerns about the nation’s reliance on foreign-made semiconductors, a vulnerability highlighted by recent supply disruptions.
Trump has suggested using tariff revenue to support U.S. farmers who may be squeezed by the new trade measures. He has argued that while agricultural producers could feel pain in the short term, tariff-driven policy shifts would ultimately benefit them. Still, it remains unclear how relief would be delivered. Any bailout plan could run into legal hurdles, with the Supreme Court preparing to weigh in on challenges to the tariff program. Lower courts have previously ruled against aspects of the administration’s trade authority, raising the possibility that billions in tariff collections could be subject to refund.
The tariff announcement arrives as the U.S. and China move toward broader trade negotiations. Reports indicate the two nations are finalizing a large aircraft purchase by Beijing, potentially involving Boeing, which could serve as a centerpiece of a wider agreement. Trump has described the discussions with Chinese President Xi Jinping as “productive,” noting that the two leaders have agreed to continue talks in the coming months.
The administration has also linked progress in trade talks with other economic and political issues. Earlier this month, the White House confirmed that Oracle would participate in a U.S.-based consortium to manage TikTok operations, part of a wider effort to reshape the economic relationship between the world’s two largest economies.
Investors remain divided on the long-term effects of the new tariffs. While supporters argue the measures will bring manufacturing jobs back to U.S. soil and strengthen domestic industries, critics warn that higher costs could be passed on to consumers and businesses, dampening growth. The pharmaceutical sector, in particular, could face significant disruption as companies weigh the high costs of reshoring production against the risk of steep import penalties.
With the 2024–2025 trade agenda expanding rapidly, the coming months will test whether the administration can balance its protectionist push with the need to maintain global supply chains and avoid further economic strain.
Cryptocurrency markets extended losses on Thursday as Bitcoin, Ether, and other digital assets tumbled in a week marked by heavy liquidations, ETF outflows, and growing caution across risk assets. The slide comes just a day before a massive $22 billion in options tied to the two largest tokens is set to expire, amplifying volatility across trading desks.
Bitcoin fell below $110,000 for the first time in four weeks, shedding more than 3% by late afternoon in New York. Ether fared worse, dropping as much as 8% intraday to below $4,000 before trimming losses. The sell-off spread quickly to smaller tokens, with Solana, Dogecoin, and Cronos posting declines of 6% to 10%.
The rout has erased more than $140 billion in market value this week, according to CoinMarketCap data. Analysts note that the pressure has been fueled by forced unwinds of leveraged positions on offshore exchanges, where opaque reporting and differing index rules can magnify price swings. More than $1.6 billion in long positions was liquidated earlier in the week, with an additional $500 million cleared in the past 24 hours alone.
Ether has faced particular selling pressure, with U.S.-listed exchange-traded funds seeing nearly $300 million in net outflows since Monday. That shift in flows has coincided with technical breakdowns, raising the risk of further liquidations if the token slips decisively below $3,800. A deeper slide could drag on listed companies that hold large amounts of Ether and Bitcoin on their balance sheets, since these so-called digital-asset treasury stocks trade as leveraged proxies for underlying coin prices.
The sell-off also weighed on publicly traded crypto-related firms. Robinhood and Coinbase both lost more than 3% on Thursday, while mining and digital asset infrastructure companies posted similar declines. Investor sentiment toward the “treasury model,” where firms hold cryptocurrencies as part of their capital strategy, has weakened as premiums over net asset value narrow and new issuance dilutes holders.
Beyond crypto-specific factors, the broader macro environment has added pressure. U.S. equities pulled back from recent record highs amid worries that enthusiasm around artificial intelligence may have overheated valuations. Uncertainty over the Federal Reserve’s interest rate path continues to ripple through risk assets. At the same time, the Treasury’s efforts to refill its General Account by issuing new debt has acted as a liquidity drain, redirecting capital away from speculative markets such as digital assets.
Despite the turbulence, Bitcoin and Ether remain among the year’s best-performing major assets, still up significantly from 2024 levels. Crypto advocates point out that historically, September has been one of the more volatile months for digital assets, with the final quarter often delivering stronger seasonal tailwinds.
Friday’s options expiry could prove pivotal. Roughly $17 billion in contracts tied to Bitcoin and $5.3 billion linked to Ether are due to roll off, a notional value large enough to trigger outsized price swings depending on how traders reposition. Market watchers suggest that whether Bitcoin can hold above $110,000 and Ether above $3,800 will help set the tone for the next leg of trading into year-end.
For now, caution is dominating sentiment, as investors weigh the possibility of further liquidations against the backdrop of one of the largest options expirations of the year.
Iconic All-American Burger Chain to Open Four Locations in Okinawa Over The Next Five Years
LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Fatburger and 17 other restaurant concepts, announces a new partnership with Green Micro Factory Inc. to bring the beloved burger brand back to Japan. Four locations will open in Okinawa over the next five years, with the first unit slated to open before the end of the year.
“Okinawa presents a strategic opportunity for our return to Japan with its robust tourism and steady foot traffic generated by its military base presence,” said Taylor Wiederhorn, Chief Development Officer of FAT Brands. “We see our debut in Okinawa as the first step in our broader growth across the country as we look to win locals over with our custom-built burgers, Fat and Skinny Fries, hand-scooped milkshakes, and more.”
Ever since the first Fatburger opened in Los Angeles over 70 years ago, the chain has been known for its delicious, grilled-to-perfection and cooked-to-order burgers. Founder Lovie Yancey believed that a big burger with everything on it is a meal in itself; at Fatburger “everything” is not just the usual roster of toppings. Burgers can be customized with everything from bacon and eggs to chili and onion rings. In addition to its famous burgers, the Fatburger menu also includes Fat and Skinny Fries, sweet potato fries, scratch-made onion rings, Impossible™ Burgers, turkeyburgers, hand-breaded crispy chicken sandwiches, and hand-scooped milkshakes made from 100 percent real ice cream.
FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets and develops fast casual, quick-service, casual and polished casual dining restaurant concepts around the world. The Company currently owns 18 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Smokey Bones, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.
About Fatburger
An all-American, Hollywood favorite, Fatburger is a fast-casual restaurant serving big, juicy, tasty burgers, crafted specifically to each customer’s liking. With a legacy spanning over 70 years, Fatburger’s extraordinary quality and taste inspire fierce loyalty amongst its fan base, which includes a number of A-list celebrities and athletes. Featuring a contemporary design and ambiance, Fatburger offers an unparalleled dining experience, demonstrating the same dedication to serving gourmet, homemade, custom-built burgers as it has since 1952 – The Last Great Hamburger Stand™.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the timing and performance of new store openings and area development agreements. Forward-looking statements reflect expectations of FAT Brands Inc. (“we” or “our”) concerning the future and are subject to significant business, economic and competitive risks, uncertainties and contingencies. These factors are difficult to predict and beyond our control, and could cause our actual results to differ materially from those expressed or implied in such forward-looking statements. We refer you to the documents that we file from time to time with the Securities and Exchange Commission, such as our reports on Form 10-K, Form 10-Q and Form 8-K, for a discussion of these and other factors. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release.
Kratos Latest Weapons-Configured Valkyrie will be On-Site
Kratos MAKO Tactical Jet Drone, the First CCA to Demonstrate Manned-Unmanned Teaming in 2015, also to be Displayed
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets and an industry-leading provider of high-performance, jet-powered unmanned aerial systems, will display tactical and target unmanned jet drones, including the latest weapons-configured Valkyrie, at the upcoming Marine Corps Air Station Miramar Air Show September 26-28. Kratos’ tactical family of unmanned jet drones is designed for a range of military operations, including strike, ISR (intelligence, surveillance, and reconnaissance), RF (radio frequency), and communications. This lineup features the latest advancements, including the XQ-58 Valkyrie, UTAP-22 Mako, Tactical Firejet, and BQM-177 target system.
The Miramar Air Show invites both domestic and international visitors to explore full-scale Kratos tactical and target aircraft systems on display. These innovative systems exemplify the future of uncrewed air technology, providing proven and affordable solutions for mass production, deployment, and military engagement. Kratos’ unique approach aligns seamlessly with the Department of Defense’s latest technology initiatives and affordability strategies, enabling systems that can operate effectively from even the most remote locations worldwide.
The XQ-58 Valkyrie is a Collaborative Combat Aircraft (CCA)/ Autonomous Collaborative Platform (ACP) designed to operate with Joint and Allied Forces. Flying since 2019, the XQ-58 continues to pioneer tactical unmanned aerial system (UAS) technology and collaborative manned-unmanned capability.
Steve Fendley, President of Kratos Unmanned Systems Division, said, “We are proud to showcase our latest drone technologies at Miramar, offering attendees a unique opportunity to see these systems in person. Kratos is a recognized leader in unmanned systems, delivering affordable, high-performance aerial platforms like the XQ-58 Valkyrie that support a wide range of national security missions with speed, agility, and innovation. The Miramar Air Show is the ideal venue to highlight Kratos’ game changing systems that represent the future.”
Eric DeMarco, President and CEO of Kratos, said, “We are once again honored to be able to display Kratos’ affordable, leading technology hardware and systems at the Miramar Air Show with our partner, the United States Marine Corps. The Marines are a demonstrated-technology innovation leader, including Kratos’ UTAP 22 Mako, a CCA that began flying manned-unmanned teaming with USMC Harrier manned jet fighters in 2015, through today with Kratos’ Valkyrie flying with USMC F-35s. Kratos will continue to work closely with the Marines, including with certain of our most recent Drone related systems and capabilities.”
Kratos’ Tactical Firejet is designed to affordably meet requirements for fast ingress and egress of tactically denied battle spaces with the ability to deliver significant payloads over long ranges at high speed.
Located in Hangar Three, visitors to Kratos’ display can also learn more about the Spartan Line of turbojet engines, showcasing unique capabilities for expendable engine applications, such as unmanned aerial systems and tactical missiles. Additionally, Kratos’ display will feature Elroy Air’s Chaparral, a hybrid-electric autonomous vertical takeoff-and-landing (VTOL) cargo drone, of which Kratos was recently announced as Elroy Air’s exclusive U.S. manufacturing partner.
Elroy Air’s Chaparral, of which Kratos is the exclusive U.S. manufacturer, is a hybrid-electric Vertical Take-Off and Landing cargo drone designed to autonomously transport 300 pounds of cargo over distances of 300 miles. Engineered for quick turnaround, efficiency, and safety, the Chaparral enables secure, uncrewed cargo delivery at a fraction of the capital and operational cost of piloted helicopters while eliminating risk to personnel in contested or high-risk logistics environments.
The Kratos Mako is a high-speed, highly maneuverable unmanned aerial system (UAS) with open mission-system flexibility and ample payload capacity to make it an affordable and highly effective solution.
Miramar Air Show attendees will have the opportunity to engage with various static displays of advanced aircraft, providing insights into the latest innovations in aviation technology. Held at Marine Corps Air Station Miramar in San Diego, California, the show also features aerial performances and dynamic flight demonstrations with cutting-edge aircraft.
With advanced aerodynamic design, the BQM-177 is a formidable high-performance target for live-fire training scenarios, including sub-sonic, sea-skimming anti-ship cruise missile accurate threat emulation.
About Kratos Defense & Security Solutions Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter.
Notice Regarding Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to a variety of matters including, without limitation, Kratos’ expectations regarding the use of the proceeds from the public offering, the pipeline for opportunities, and Kratos’ success with respect to such opportunities, as well as other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements including, but not limited to: risks and uncertainties related to market conditions as well as general economic factors. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.
U.S. jobless claims unexpectedly declined last week, signaling continued resilience in the labor market even as hiring has slowed and the Federal Reserve keeps a close eye on economic momentum.
Initial claims for unemployment benefits totaled a seasonally adjusted 218,000 for the week ending Sept. 20, according to the Labor Department. That was a drop of 14,000 from the prior week’s upwardly revised level and came in well below the consensus forecast of 235,000. Continuing claims, which measure those still receiving benefits, edged slightly lower to 1.926 million.
The latest claims figures arrive against a backdrop of uncertainty about the economy’s trajectory. Payroll growth has cooled, and job openings remain at multiyear lows. The Fed recently responded by cutting its benchmark borrowing rate by a quarter percentage point to a range of 4% to 4.25%, its first reduction of 2025. Policymakers cited rising risks to employment as one factor behind the decision.
Still, the claims data suggests companies remain hesitant to lay off workers despite a noticeable pullback in hiring. Volatility in weekly figures continues, with Texas accounting for a sizable portion of recent swings, but the broader picture points to a labor market that is holding firmer than many expected.
Beyond the employment data, Thursday also brought signs of strength in other corners of the economy. Gross domestic product for the second quarter was revised sharply higher to an annualized gain of 3.8%. That marked a half-point improvement from the prior estimate and reflected stronger consumer spending than initially reported. Personal consumption, which makes up about two-thirds of U.S. economic activity, rose at a 2.5% pace, well above earlier estimates and the tepid 0.6% increase seen in the first quarter.
Durable goods orders added to the positive picture. Purchases of long-lasting items such as appliances, aircraft, and computers climbed 2.9% in August, defying forecasts for a decline and reversing a steep drop from July. Even excluding transportation equipment, orders grew 0.4% in the month and 1.9% when defense-related spending was excluded, underscoring broad-based demand.
The housing sector, which has been under pressure from higher borrowing costs, also showed signs of improvement. Sales of newly built homes jumped 20.5% in August, the largest monthly gain since early 2022. Existing home sales came in slightly ahead of expectations at an annualized rate of 4 million.
Taken together, the data paints a picture of an economy that continues to expand despite headwinds from tighter credit conditions, shifting trade policies, and global geopolitical challenges. Markets currently anticipate that the Fed will follow through with two more rate cuts before the end of the year, at its October and December meetings.
While policymakers acknowledge that growth is being restrained by elevated borrowing costs, they also see resilience across consumer spending, business investment, and labor markets. That combination has kept the outlook more balanced than some had feared heading into the final stretch of 2025.
Lottery.com’s International Gaming Platform Launch Accelerates Revenue Outlook
FORT WORTH, Texas, Sept. 24, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (the “Company” or “SEGG Media”) the global sports, entertainment, and gaming conglomerate, today announced the official launch of its international gaming platform at https://international.lottery.com. Players outside of the U.S. can visit the site today, create an account, and sample many games for free.
The strategic decision to bring operations in house to launch Lottery.com International will maximize revenue potential. The gaming platform was an asset acquired as part of the Company’s purchase of Spektrum Ltd. earlier this year. Lottery.com International will deploy the gaming platform in the global markets across Europe, Africa, and other high-growth territories and is projected to deliver approximately $6,350,000 in the coming FISCAL year (2026); marking an acceleration to the Company’s revenue outlook and sustained balance sheet growth.
Matthew McGahan, Chairman of SEGG Media, said: “This is another example of how the Company’s buy-and build strategy is allowing us to execute at speed and scale. We are confident in our ability to generate revenue from international gaming operations in the near term, and our mission is clear: to deliver long-term value for our shareholders and redefine the gaming experience for customers worldwide. This is about delivering results, quarter after quarter, and positioning SEGG Media as a leader in global gaming, including lottery.”
Tim Scoffham, CEO of Sports.com Media Group and Lottery.com International, added: “This is not just a launch — it’s a momentum shift. Letting consumers across the globe try our gaming platform provides a risk-free opportunity to introduce Lottery.com to millions of players around the world. Our strategy is disciplined operations, strategic expansion, rapid market penetration and capitalizing on the enormous opportunity at the convergence of sports, entertainment, and gaming.”
The Company’s international rollout represents a significant growth catalyss for the Company. By combining enhanced technology, local market execution, and SEGG Media’s buy-and-build approach, the Company is expected to scale revenues rapidly, drive higher multiples, and unlock shareholder value. Real money gaming will be made available to players on the platform in select jurisdictions starting in November. The Company will continue to allow players to enjoy free games in most markets as real money options are made available.
About SEGG Media Corporation SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to: the Company’s ability to secure additional capital resources; the Company’s ability to continue as a going concern; the Company’s ability to complete acquisitions; the Company’s ability to remain in compliance with Nasdaq Listing Rules; and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.
For additional information, visit www.seggmediacorp.com or contact media relations at media@seggmediacorp.com.
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC)
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced today that the National Institutes of Health (NIH) has awarded a $2.3 million grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC).
The grant is intended to support expenses related to the enrollment of U.S. patients who are resistant to chemo and immunotherapy. The NIH grant allocations will be distributed over three years from 2025-2027.
“We are thrilled to receive this prestigious NIH grant for the expansion of our Phase 2 trial. It’s a great honor to have the support of the National Institutes of Health as we seek to further validate the efficacy of our lead agent ateganosine and its potential to be a breakthrough treatment within the vastly underserved NSCLC market,” said CEO Vlad Vitoc, M.D. “With the clearance of FDA Investigational New Drug (IND) for THIO-101 in 2023, we can begin enrolling U.S. patients in the expansion phase of the trial immediately.”
“The NIH grant is a tremendous achievement and a testament to the dedication, collaboration, and hard work of everyone involved in the clinical development of ateganosine,” added Victor Zaporojan, M.D., MAIA’s senior medical director. “Ateganosine represents a potential solution for the significant unmet clinical need in third-line NSCLC, where no established standard of care exists and where the overall survival outcomes observed with ateganosine have not been achieved by other therapies. By enrolling patients in the United States, our trial will gain access to a substantially larger patient pool across multiple continents, further strengthening the impact and relevance of our study.”
In Parts A and B of THIO-101, median overall survival (OS) for the 22 patients in third-line treatment was 17.8 months as of June 30, 2025, with a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months. The first patient in the expansion of the trial was dosed in July 2025 in Taiwan.
Research referenced in this press release is supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA309843. The content is solely the responsibility of MAIA and does not necessarily represent the official views of the National Institutes of Health.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-101 Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Shares of Lithium Americas (NYSE: LAC) soared nearly 100% on Wednesday after reports that the Trump administration is considering taking a stake in the company as part of a renegotiated federal loan package tied to the development of the Thacker Pass lithium mine in Nevada.
According to Reuters, the administration is seeking as much as a 10% equity stake in the Vancouver-based miner. The proposed arrangement comes as Lithium Americas works through terms of a $2.26 billion loan from the Department of Energy, originally granted during the first Trump administration.
Under the current negotiations, the company has offered the government no-cost warrants for up to 10% of its common stock. At the same time, the administration is reportedly pressing General Motors (NYSE: GM) — which owns a 38% stake in Thacker Pass and has invested $625 million — for purchase guarantees that would help shore up demand for the lithium produced at the site. GM shares ticked higher by more than 2% on the news.
A Strategic Lithium Project
Thacker Pass is expected to play a central role in U.S. energy security. Once operational, the project is projected to be the largest lithium mining operation in the Western Hemisphere. Its first production phase, slated for 2028, is forecast to produce more than 40,000 metric tons of lithium carbonate annually — enough to power batteries for roughly 800,000 electric vehicles.
For perspective, Albemarle’s (NYSE: ALB) Silver Peak mine in Nevada, currently the only operating lithium mine in the U.S., produces fewer than 5,000 metric tons per year. This makes Thacker Pass a significant leap in domestic production capacity at a time when global demand for electric vehicles, battery storage, and clean energy technologies is surging.
China currently dominates the global lithium industry, producing more than 40,000 metric tons per year and refining more than 65% of the world’s supply. By comparison, the U.S. refines less than 3%. This imbalance has made lithium one of the most strategically sensitive commodities in the energy transition.
“Lithium is the new oil,” said one energy analyst, noting that securing supply has become a cornerstone of U.S. industrial policy. “Without it, you can’t scale EV adoption or battery storage, and that makes projects like Thacker Pass crucial to long-term energy independence.”
The government’s interest in Lithium Americas follows similar moves to shore up domestic supply chains for other critical materials. In July, MP Materials (NYSE: MP) announced a multibillion-dollar deal with the Department of Defense that made the government its largest shareholder, boosting MP’s stock more than 50%. Meanwhile, Intel (NASDAQ: INTC) has climbed over 25% since talks of a potential government stake in the chipmaker became public.
This pattern underscores the administration’s strategy of leveraging federal investment to reduce reliance on foreign sources of essential resources, from rare earth elements to semiconductors.
Lithium Americas stock traded at $6.09 as of 2:08 p.m. EDT, up more than 98% on the day. The sharp rally comes despite ongoing weakness in lithium prices, which have fallen over the past year amid oversupply from China. Futures for lithium carbonate are down more than 12%, while lithium hydroxide has dropped more than 4.5%.
Those price pressures have raised concerns about the financial viability of large-scale U.S. mining projects. The administration’s involvement could provide a stabilizing force, ensuring that key projects like Thacker Pass remain on track. The first loan draw is expected this month, with construction at the Nevada site already underway.
For now, investors appear to be betting that federal backing — and a potential government equity stake — could cement Lithium Americas’ role as a cornerstone of America’s clean energy future.
Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Milestone in Findhelp partnership. SelectQuote announced that it has referred more than 200,000 low-income seniors to Findhelp, with nearly 50,000 of those individuals accessing free or reduced-cost services. The milestone demonstrates SelectQuote’s role in addressing the needs of Medicare-eligible consumers.
Partnership connects consumers to critical support. Findhelp is a closed-loop referral management software platform that connects individuals with community resources such as food, housing, transportation, and financial aid. SelectQuote has partnered with Findhelp for several years, directing seniors to assistance programs. The initiative does not generate revenue, but it extends SelectQuote’s Medicare distribution model by providing tangible value to consumers.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Integral Ad Science (Nasdaq: IAS), a global leader in media measurement and optimization, announced Wednesday that it has entered into a definitive agreement to be acquired by Novacap, a North American private equity firm, in a transaction valued at approximately $1.9 billion.
Under the deal, Novacap will purchase all outstanding shares of IAS for $10.30 per share in cash, representing a roughly 22% premium over the company’s closing price on September 23. The agreement, which has been unanimously approved by IAS’s board of directors, is expected to close before the end of 2025, pending regulatory approvals.
Once finalized, IAS will become a privately held company and its shares will no longer trade on public markets. Current shareholder Vista Equity Partners, which played a significant role in expanding IAS’s AI-powered platform and customer base, will exit its investment upon completion of the deal.
For IAS, the acquisition represents a chance to accelerate its growth and innovation strategy in digital media quality. CEO Lisa Utzschneider highlighted the move as a milestone that will provide the company with the resources and flexibility to expand its AI-first measurement and optimization platform.
“Our mission has always been to set the global benchmark for trust and transparency in digital media quality,” Utzschneider said in a statement. “With Novacap’s support, we’ll be able to further scale our platform and deliver even more value to advertisers, publishers, and media partners.”
Novacap, which manages more than $10 billion in assets, sees IAS as a category leader with significant potential. Samuel Nasso, a partner at the firm, said Novacap plans to work closely with IAS leadership to accelerate innovation and strengthen its solutions for global brands and publishers.
The transaction is not subject to any financing conditions, and a majority of IAS shareholders have already approved the deal through written consent. Financial advisory roles were split, with Jefferies advising IAS and Evercore advising Novacap. Legal counsel was provided by Kirkland & Ellis for IAS and Willkie Farr & Gallagher for Novacap.
Founded in 2009, IAS has established itself as a trusted player in the digital advertising ecosystem, providing data and tools to ensure ads are viewable, brand-safe, and optimized for performance. By joining forces with Novacap, the company is expected to sharpen its competitive edge and continue expanding its role as a benchmark for media transparency in the rapidly evolving adtech landscape.
If the transaction closes on schedule, IAS will continue operating under its existing name and brand while shifting into private ownership under Novacap.
Pfizer Inc. (NYSE: PFE) has announced plans to acquire Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company developing next-generation obesity and cardiometabolic treatments. The all-cash deal, valued at $47.50 per share, represents an enterprise value of approximately $4.9 billion, with the potential for an additional $22.50 per share in contingent milestone payments tied to clinical and regulatory approvals.
The acquisition marks Pfizer’s most significant push yet into the rapidly growing obesity treatment market, an area forecasted to reach hundreds of billions in value globally over the coming decade. With over 200 health conditions linked to obesity, pharmaceutical companies are racing to develop therapies that offer stronger efficacy, fewer side effects, and more convenient dosing schedules.
Metsera brings to Pfizer a diverse pipeline of incretin and amylin programs, including both injectable and oral formulations designed to improve weight loss outcomes. Its lead candidates include:
MET-097i, a weekly and monthly injectable GLP-1 receptor agonist currently in Phase 2 trials.
MET-233i, a monthly amylin analog in Phase 1 development, being tested both as monotherapy and in combination with MET-097i.
Two oral GLP-1 receptor agonist candidates expected to begin clinical trials in the near term.
Additional preclinical nutrient-stimulated hormone therapeutics under development.
Preliminary clinical data for MET-233i presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) indicated a potentially best-in-class profile, with strong durability and tolerability supporting less frequent injections.
Pfizer expects to leverage its global clinical, manufacturing, and commercial infrastructure to accelerate the development of Metsera’s portfolio. The acquisition aligns with the company’s broader strategy of expanding into high-growth therapeutic areas where demand is accelerating.
Under the agreement, Metsera shareholders will receive $47.50 in cash upon closing, with the possibility of an additional $22.50 per share through contingent value rights (CVRs). These CVRs include:
$5 per share upon the initiation of a Phase 3 trial for the MET-097i + MET-233i combination.
$7 per share upon U.S. FDA approval of MET-097i as a monthly monotherapy.
$10.50 per share upon FDA approval of the monthly MET-097i + MET-233i combination.
If all milestones are achieved, the transaction value could exceed $7 billion.
The deal has been unanimously approved by both companies’ boards of directors and is expected to close in the fourth quarter of 2025, subject to regulatory approval and shareholder consent.
With this acquisition, Pfizer joins competitors such as Eli Lilly and Novo Nordisk in intensifying the race to dominate the obesity treatment market. By combining Metsera’s innovative science with Pfizer’s scale, the company aims to deliver next-generation weight management solutions to millions of patients worldwide.
